»Go to related Japanese page in JPubb
»Go to "Pharmaceuticals" Company Directory


Loading

Press Releases from "Pharmaceuticals" Non-listed Companies

« Previous12345678910Next »
1 - 50 of 500 for your search
Mitsubishi Tanabe Pharma Corporation Strategically Strengthens Its Foundation in the Field of Inflammatory Bowel Disease Mitsubishi Tanabe Pharma signs co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA for an indication of Crohn’s disease
[ Mitsubishi Tanabe Pharma Corporation | 2017-02-03]
Biogen and Mitsubishi Tanabe Pharma Terminate the License Agreement on MT-1303
[ Mitsubishi Tanabe Pharma Corporation | 2017-01-27]
Basic Agreement on the Establishment of a Joint Venture
[ Mitsubishi Tanabe Pharma Corporation | 2016-11-07]
Announcement of FY2016 2nd Quarter Financial Results
[ Mitsubishi Tanabe Pharma Corporation | 2016-11-01]
Mitsubishi Tanabe Pharma Takes on the Challenge of Cell Therapy with the Conclusion of an Invossa Licensing Agreement with Kolon Life Science Aiming for therapy that addresses unmet medical needs in the treatment of knee osteoarthritis
[ Mitsubishi Tanabe Pharma Corporation | 2016-11-01]
Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2017
[ Mitsubishi Tanabe Pharma Corporation | 2016-10-25]
Joint research identifies hit compounds for the development of a new treatment for malaria Mitsubishi Tanabe Pharma uses its compound library in joint research activities with Medicines for Malaria Venture ―Targeting treatments for infectious diseases that burden the developing world―
[ Mitsubishi Tanabe Pharma Corporation | 2016-10-05]
Execution of Basic Agreement for Sales Anti-Allergy Agent, Rupatadine Tablets
[ Mitsubishi Tanabe Pharma Corporation | 2016-10-04]
Application for partial change in administration/dosage for Crohn's disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibody
[ Mitsubishi Tanabe Pharma Corporation | 2016-09-06]
FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS
[ Mitsubishi Tanabe Pharma Corporation | 2016-08-30]
Valixa Tablet 450mg Approval for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients
[ Mitsubishi Tanabe Pharma Corporation | 2016-08-26]
Application filed in Japan fortype 2 diabetes mellitus treatment agent combination drug - Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets -
[ Mitsubishi Tanabe Pharma Corporation | 2016-08-23]
Announcement of FY2016 1st Quarter Financial Results
[ Mitsubishi Tanabe Pharma Corporation | 2016-08-02]
Regarding Nomination Committee and Compensation Committee
[ Mitsubishi Tanabe Pharma Corporation | 2016-06-22]
Mitsubishi Tanabe Pharma Submits New Drug Application for Edaravone to Treat ALS in the United States
[ Mitsubishi Tanabe Pharma Corporation | 2016-06-20]
Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund
[ Mitsubishi Tanabe Pharma Corporation | 2016-06-06]
Approval of REMICADE for I.V. Infusion 100, an Anti-Human TNFα Monoclonal Antibody, for a Partial Change in Dosage and Usage in Psoriasis
[ Mitsubishi Tanabe Pharma Corporation | 2016-05-13]
Notice of Dividend of Retained Earnings
[ Mitsubishi Tanabe Pharma Corporation | 2016-05-11]
Change of Representative Director, Director and Corporate Auditor
[ Mitsubishi Tanabe Pharma Corporation | 2016-04-27]
MT Pharma Singapore Pte. Ltd. Starts Business Operations Mitsubishi Tanabe Pharma's Subsidiary in Singapore
[ Mitsubishi Tanabe Pharma Corporation | 2016-04-04]
Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries
[ Mitsubishi Tanabe Pharma Corporation | 2016-03-29]
Valixa Tablet 450 mg Application for Additional Indication in Japan for the Prevention of CMV disease in organ transplant patients Public Knowledge-based Application
[ Mitsubishi Tanabe Pharma Corporation | 2016-03-22]
Notice regarding change of current commercialization scheme to new strategic co-promotion partnership in Japan for RA treatment agent Simponi subcutaneous injection 50 mg syringe (generic name: golimumab)
[ Mitsubishi Tanabe Pharma Corporation | 2016-03-10]
Mitsubishi Tanabe Pharma Enhances Operations in the United States
[ Mitsubishi Tanabe Pharma Corporation | 2016-02-23]
Announcement of FY2015 3rd Quarter Financial Results
[ Mitsubishi Tanabe Pharma Corporation | 2016-02-03]
Notice Regarding Results of Early Retirement Program
[ Mitsubishi Tanabe Pharma Corporation | 2016-02-03]
Aiming to contribute to psoriasis treatment in Japan, Contract signed for strategic co-promotion for Ixekizumab, Humanized Anti-Interleukin-17 Monoclonal Antibody
[ Torii Pharmaceutical Co., Ltd. | 2016-01-08]
Torii files a New Drug Application for TO-206, an Allergen Immunotherapy Tablet for Japanese Cedar Pollinosis
[ Torii Pharmaceutical Co., Ltd. | 2015-12-25]
Remicade for I.V. Infusion 100 Approval of Additional Indication for Kawasaki Disease World First Biologic Treatment
[ Mitsubishi Tanabe Pharma Corporation | 2015-12-21]
RADICUT inj. 30mg and RADICUT BAG for I.V. Infusion 30mg An import and Marketing Permission for ALS in South Korea
[ Mitsubishi Tanabe Pharma Corporation | 2015-12-21]
RADICUT inj. 30mg and RADICUT Infusion inj. 30mg An import and Marketing Permission for ALS in South Korea
[ Mitsubishi Tanabe Pharma Corporation | 2015-12-21]
Announcement of Collaboration of Promotional Activities for Daina screen®・HIV Combo For Human Immunodeficiency Virus Type 1(HIV-1) p24 antigen & antibodies to HIV-1 and HIV- 2 Detection Test Kit
[ Torii Pharmaceutical Co., Ltd. | 2015-12-18]
Akebia and Mitsubishi Tanabe Pharma Announce Collaboration to Develop and Commercialize Vadadustat in Asia
[ Mitsubishi Tanabe Pharma Corporation | 2015-12-15]
Formulation of the Medium-Term Management Plan 16-20: Open Up the Future
[ Mitsubishi Tanabe Pharma Corporation | 2015-11-30]
Price Listing on the NHI Reimbursement List and Launch of “MITICURE® House Dust Mite Sublingual Tablets” an Allergen Immunotherapy Tablet for House Dust Mite Allergy
[ Torii Pharmaceutical Co., Ltd. | 2015-11-26]
Launch of “Allergen Scratch Extract Positive control (Torii) Histamine Dihydrochloride”in Japan
[ Torii Pharmaceutical Co., Ltd. | 2015-11-26]
NHI Reimbursement Price Listing and Launch of the Novel Antitumor Agent “Yondelis® IV Infusion”
[ Taiho Pharmaceutical Co., Ltd. | 2015-11-26]
Announcement of an approval for an additional indication for the Anti-depressant, Lexapro Tablets 10 mg in Japan
[ Mitsubishi Tanabe Pharma Corporation | 2015-11-20]
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan
[ Taiho Pharmaceutical Co., Ltd. | 2015-11-13]
Novel anti-HIV drug Genvoya® received US regulatory approval, JT’s partner Gilead Sciences announced
[ Torii Pharmaceutical Co., Ltd. | 2015-11-06]
Announcement of FY2015 2nd Quarter Financial Results
[ Mitsubishi Tanabe Pharma Corporation | 2015-10-30]
Notice Regarding Implementation of Early Retirement Program
[ Mitsubishi Tanabe Pharma Corporation | 2015-10-30]
Medicago Engaged by the Canadian Government Produce Ebola Monoclonal Antibodies
[ Mitsubishi Tanabe Pharma Corporation | 2015-10-30]
Mitsubishi Tanabe Pharma and Regeneron Conclude Collaboration Agreement for Fasinumab, NGF Antibody
[ Mitsubishi Tanabe Pharma Corporation | 2015-10-02]
Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016
[ Mitsubishi Tanabe Pharma Corporation | 2015-09-30]
New Drug Application Approval of “MITICURE® House Dust Mite Sublingual Tablets” an Allergen Immunotherapy Tablet for House Dust Mite Allergy in Japan
[ Torii Pharmaceutical Co., Ltd. | 2015-09-28]
MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer
[ Mitsubishi Tanabe Pharma Corporation | 2015-09-23]
Notice Regarding Worldwide Patent and Know-how Transfer, Excluding Japan and Certain Other Territories in Asia, for TA-8995 (CETP inhibitor), a Treatment Agent for Dyslipidemia
[ Mitsubishi Tanabe Pharma Corporation | 2015-09-17]
MT-4666 in Alzheimer’s Disease Discontinuation of Global Phase 3 Clinical Trial Program in Japan
[ Mitsubishi Tanabe Pharma Corporation | 2015-09-15]
Biogen and Mitsubishi Tanabe Pharma Conclude a License Agreement on MT-1303, a Therapeutic Agent for Autoimmune Diseases
[ Mitsubishi Tanabe Pharma Corporation | 2015-09-09]
« Previous12345678910Next »


What's New
Top Searches

Keyword

Company
1. Maruha Nichiro Corp.
2. Kubota Corporation
3. Ikegami Tsushinki Co., Ltd.
4. Ministry of Justice
5. GOURMET NAVIGATOR INC.

Industry
1. Construction
2. Media & Telecoms
3. Real Estate
4. Pharmaceuticals
5. Services

Prefecture
1. Osaka
2. Okinawa
3. Ishikawa
4. Okayama
5. Saitama

Stock Exchange
1. SSE (Sapporo) ALL
2. TSE2(STANDARD)
3. NSE2(MAIN)
4. FSE (Fukuoka) ALL
5. NSE (Nagoya) ALL

Press Conferense Videos
Sharp and Semiconductor Energy Laboratory Jointly Develop New Oxide Semiconductor Technology That Will Revolutionize Displays Sharp and Semiconductor Energy Laboratory Jointly Develop New Oxide Semiconductor Technology That Will Revolutionize Displays
Sharp Corporation 2012/06/01
More Videos
Latest Press Release Search

Save favorite searches Hot keywords

Fukushima | power supply | cloud | solar
*NOTE: Recommended keywords shown above.
Your Most Recently Viewed Companies
Visit any of the company pages in JPubb, and your most recently viewed companies will automatically show up here.

Erase all This feature:ON How to use
Most Popular: Pharmaceuticals
1. Proton Pump Inhibitor ACIPHEX 20 mg Receives Approval for Short-Term Treatment of GERD in Adolescents in United States
Eisai Co., Ltd. 2008/07/01
2. Eisai Signs License Agreement in Europe for an Anti-epileptic Drug
Eisai Co., Ltd. 2009/02/20
3. Notification with Respect to Issuance of Unsecured Straight Bonds
Eisai Co., Ltd. 2008/05/29
4. HUMIRA® received approval for the treatment of rheumatoid arthritis in Japan
Eisai Co., Ltd. 2008/04/16
5. Notice Regarding Administrative Action Related to Violation of Pharmaceutical Affairs Law
Mitsubishi Tanabe Pharma Corporation 2010/04/13
Feed
Releases by Prefecture
Hokkaido | Aomori | Iwate | Miyagi | Akita | Yamagata | Fukushima

Ibaraki | Tochigi | Gunma | Saitama | Chiba | Tokyo | Kanagawa

Niigata | Toyama | Ishikawa | Fukui | Yamanashi | Nagano

Gifu | Shizuoka | Aichi | Mie

Shiga | Kyoto | Osaka | Hyogo | Nara | Wakayama

Tottori | Shimane | Okayama | Hiroshima | Yamaguchi

Tokushima | Kagawa | Ehime | Kochi

Fukuoka | Saga | Nagasaki | Kumamoto | Oita | Miyazaki | Kagoshima | Okinawa
Releases by Stock Exchange
TSE (Tokyo) All | TSE1(PRIME) | TSE2(STANDARD) | TSE Growth | TOKYO PRO Market

NSE (Nagoya) All | NSE1(PREMIER) | NSE2(MAIN) | NSE NEXT | NSE-only

SSE (Sapporo) All | Ambitious | SSE-only

FSE (Fukuoka) All | Q-Board | FSE-only
Press Release Search
Company
Industry
Prefecture
Stock Exchange
Date
(yyyy/mm/dd)		 //～
//
Listed or Non-listed
*NOTE: Please input only items to be specified.
*NOTE: The "date" here means the one on which a press release is uploaded on this website. So it isn't necessarily the same as its official announcement date.
Company Search
Company
Industry
Prefecture
Stock Exchange
Listed or Non-listed
*NOTE: Please input only items to be specified.